Literature DB >> 19047679

BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.

Joji Nakayama1, Mutsumi Yamamoto, Katsuhiko Hayashi, Hitoshi Satoh, Kenji Bundo, Masato Kubo, Ryo Goitsuka, Michael A Farrar, Daisuke Kitamura.   

Abstract

Pre-B-cell leukemia spontaneously develops in BLNK-deficient mice, and pre-B-cell acute lymphoblastic leukemia cells in children often lack BLNK protein expression, demonstrating that BLNK functions as a tumor suppressor. However, the mechanism by which BLNK suppresses pre-B-cell leukemia, as well as the identification of other genetic alterations that collaborate with BLNK deficiency to cause leukemogenesis, are still unknown. Here, we demonstrate that the JAK3/STAT5 signaling pathway is constitutively activated in pre-B leukemia cells derived from BLNK(-/-) mice, mostly due to autocrine production of IL-7. Inhibition of IL-7R signaling or JAK3/STAT5 activity resulted in the induction of p27(kip1) expression and cell-cycle arrest, accompanied by apoptosis in the leukemia cells. Transgene-derived constitutively active STAT5 (STAT5b-CA) strongly synergized with the loss of BLNK to initiate leukemia in vivo. In the leukemia cells, exogenously expressed BLNK inhibited autocrine JAK3/STAT5 signaling, resulting in p27(kip1) induction, cell-cycle arrest, and apoptosis. BLNK-inhibition of JAK3 was dependent on the binding of BLNK to JAK3. These data indicate that BLNK normally regulates IL-7-dependent proliferation and survival of pre-B cells through direct inhibition of JAK3. Thus, somatic loss of BLNK and concomitant mutations leading to constitutive activation of Jak/STAT5 pathway result in the generation of pre-B-cell leukemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047679      PMCID: PMC2644075          DOI: 10.1182/blood-2008-07-166355

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  Regulation of B-cell fate by antigen-receptor signals.

Authors:  Hiroaki Niiro; Edward A Clark
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

2.  Distinct signaling requirements for Dmu selection, IgH allelic exclusion, pre-B cell transition, and tumor suppression in B cell progenitors.

Authors:  Katsuhiko Hayashi; Mutsumi Yamamoto; Takuya Nojima; Ryo Goitsuka; Daisuke Kitamura
Journal:  Immunity       Date:  2003-06       Impact factor: 31.745

3.  Association of SLP-65/BLNK with the B cell antigen receptor through a non-ITAM tyrosine of Ig-alpha.

Authors:  N Engels; B Wollscheid; J Wienands
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

4.  The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion.

Authors:  Alexandra Flemming; Tilman Brummer; Michael Reth; Hassan Jumaa
Journal:  Nat Immunol       Date:  2002-11-18       Impact factor: 25.606

Review 5.  STAT proteins: novel molecular targets for cancer drug discovery.

Authors:  J Turkson; R Jove
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

6.  Constitutive activation of Stat5a by retrovirus integration in early pre-B lymphomas of SL/Kh strain mice.

Authors:  Tatsuaki Tsuruyama; Takuro Nakamura; Guang Jin; Munetaka Ozeki; Yoshihiro Yamada; Hiroshi Hiai
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

7.  IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development.

Authors:  Runqing Lu; Kay L Medina; David W Lancki; Harinder Singh
Journal:  Genes Dev       Date:  2003-06-27       Impact factor: 11.361

8.  Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia.

Authors:  Hassan Jumaa; Lukas Bossaller; Karina Portugal; Bettina Storch; Michael Lotz; Alexandra Flemming; Martin Schrappe; Ville Postila; Pekka Riikonen; Jukka Pelkonen; Charlotte M Niemeyer; Michael Reth
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

9.  Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Authors:  Ken Murata; Hidetoshi Kumagai; Toshiyuki Kawashima; Kaori Tamitsu; Mariko Irie; Hideaki Nakajima; Shinya Suzu; Masabumi Shibuya; Shimeru Kamihira; Tetsuya Nosaka; Shigetaka Asano; Toshio Kitamura
Journal:  J Biol Chem       Date:  2003-06-18       Impact factor: 5.157

10.  Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells.

Authors:  Rogier Kersseboom; Sabine Middendorp; Gemma M Dingjan; Katarina Dahlenborg; Michael Reth; Hassan Jumaa; Rudolf W Hendriks
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

View more
  43 in total

Review 1.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

2.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.

Authors:  Rahul Nahar; Parham Ramezani-Rad; Maximilian Mossner; Cihangir Duy; Leandro Cerchietti; Huimin Geng; Sinisa Dovat; Hassan Jumaa; B Hilda Ye; Ari Melnick; Markus Müschen
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

3.  Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3.

Authors:  Jamshed Warsi; Bernat Elvira; Rosi Bissinger; Zohreh Hosseinzadeh; Florian Lang
Journal:  J Membr Biol       Date:  2015-06-23       Impact factor: 1.843

4.  It is a differentiation game: STAT5 in a new role.

Authors:  Barbara Maurer; Matthias Farlik; Veronika Sexl
Journal:  Cell Death Differ       Date:  2017-05-12       Impact factor: 15.828

5.  Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL.

Authors:  Gabriel J Sandoval; Daniel B Graham; Grzegorz B Gmyrek; Holly M Akilesh; Keiko Fujikawa; Benedicte Sammut; Deepta Bhattacharya; Shuba Srivatsan; Alfred Kim; Andrey S Shaw; Katherine Yang-Iott; Craig H Bassing; Eric Duncavage; Ramnik J Xavier; Wojciech Swat
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

6.  Pre-B cell receptor signaling in acute lymphoblastic leukemia.

Authors:  Rahul Nahar; Markus Müschen
Journal:  Cell Cycle       Date:  2009-12-09       Impact factor: 4.534

7.  Cutting edge: cell-autonomous control of IL-7 response revealed in a novel stage of precursor B cells.

Authors:  Gabriel J Sandoval; Daniel B Graham; Deepta Bhattacharya; Barry P Sleckman; Ramnik J Xavier; Wojciech Swat
Journal:  J Immunol       Date:  2013-02-18       Impact factor: 5.422

8.  NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Authors:  Byung-Hak Kim; Jun-Goo Jee; Chang-Hong Yin; Claudio Sandoval; Somasundaram Jayabose; Daisuke Kitamura; Erika A Bach; Gyeong-Hun Baeg
Journal:  Mol Cancer       Date:  2010-02-11       Impact factor: 27.401

9.  BCL6 is critical for the development of a diverse primary B cell repertoire.

Authors:  Cihangir Duy; J Jessica Yu; Rahul Nahar; Srividya Swaminathan; Soo-Mi Kweon; Jose M Polo; Ester Valls; Lars Klemm; Seyedmehdi Shojaee; Leandro Cerchietti; Wolfgang Schuh; Hans-Martin Jäck; Christian Hurtz; Parham Ramezani-Rad; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; Ignacio Moreno de Alborán; Ari M Melnick; B Hilda Ye; Markus Müschen
Journal:  J Exp Med       Date:  2010-05-24       Impact factor: 14.307

10.  Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.

Authors:  Daniel Trageser; Ilaria Iacobucci; Rahul Nahar; Cihangir Duy; Gregor von Levetzow; Lars Klemm; Eugene Park; Wolfgang Schuh; Tanja Gruber; Sebastian Herzog; Yong-mi Kim; Wolf-Karsten Hofmann; Aihong Li; Clelia Tiziana Storlazzi; Hans-Martin Jäck; John Groffen; Giovanni Martinelli; Nora Heisterkamp; Hassan Jumaa; Markus Müschen
Journal:  J Exp Med       Date:  2009-07-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.